Hydrochloric Acid

Hydrochloric Acid

SCHEMBL6402378

CC(C)=[Zr+2](C1C=C(C(C)c2ccccc2)c2ccccc21)C1C=C(C(C)c2ccccc2)c2ccccc21.[Cl-].[Cl-]

nearest known ligand 0.36

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.36
POLB P06746 1/20 0.36
KMT2A Q03164 1/20 0.36
ATM Q13315 1/20 0.36
TYR P14679 1/20 0.33
ADRA2A P08913 1/20 0.31
ADRA2C P18825 1/20 0.31
LMNA P02545 1/20 0.31
HIF1A Q16665 1/20 0.31
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6403063 0.87 POLB (0.33) MEN1POLBKMT2AATM
Hydrochloric Acid SCHEMBL5702681 0.85 PTPN1 (0.35) POLB
Hydrochloric Acid SCHEMBL6402933 0.82 MEN1 (0.37) MEN1POLBKMT2AATM
Hydrochloric Acid SCHEMBL6407273 0.79 L3MBTL1 (0.31)
Hydrochloric Acid SCHEMBL6406154 0.77
Hydrochloric Acid SCHEMBL6406449 0.77 MEN1 (0.33) MEN1POLBKMT2AATMADRA2A
Hydrochloric Acid SCHEMBL6407262 0.76 MEN1 (0.33) MEN1POLBKMT2AATM
Hydrochloric Acid SCHEMBL6402654 0.75 BCHE (0.32)
Hydrochloric Acid SCHEMBL6406815 0.74 BCHE (0.34) ALDH1A1
Hydrochloric Acid SCHEMBL5702765 0.73 POLB (0.33) POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1017729-B1 PROCESS FOR THE PREPARATION OF SUBSTANTIALLY AMORPHOUS ALPHA-OLEFIN POLYMERS, COMPOSITIONS CONTAINING THEM AND PROCESS FOR THE PREPARATION OF BRIDGED LIGAND BASELL POLYOLEFINE GMBH (DE) 2005-09-14 EP disclosed
US-6844288-B2 Process for the preparation of ligands for metallogene catalysts BASELL POLYOLEFINE GMBH (DE) 2005-01-18 US disclosed
US-20030158356-A1 Process for the preparation of substantially amorphous alpha-olefin polymers and compositions containing them and process for the preparation of bridged ligand EQUISTAR CHEMICALS, LP 2003-08-21 US disclosed
US-20020169260-A1 Process for the preparation of ligands for metallocene catalysts RESCONI LUIGI (IT) 2002-11-14 US disclosed
US-6423796-B1 COORDINATION CATALYST BASEL TECHNOLOGY COMPANY BV (NL) 2002-07-23 US disclosed
WO-2000001738-A9 PROCESS FOR THE PREPARATION OF SUBSTANTIALLY AMORPHOUS ALPHA-OLEFIN POLYMERS, COMPOSITIONS CONTAINING THEM AND PROCESS FOR THE PREPARATION OF BRIDGED LIGAND MONTELL TECHNOLOGY COMPANY BV (NL) 2000-07-27 WO disclosed
EP-1017729-A2 PROCESS FOR THE PREPARATION OF SUBSTANTIALLY AMORPHOUS ALPHA-OLEFIN POLYMERS, COMPOSITIONS CONTAINING THEM AND PROCESS FOR THE PREPARATION OF BRIDGED LIGAND Montell Technology Company bv (NL) 2000-07-12 EP disclosed
WO-2000001738-A2 PROCESS FOR THE PREPARATION OF SUBSTANTIALLY AMORPHOUS ALPHA-OLEFIN POLYMERS, COMPOSITIONS CONTAINING THEM AND PROCESS FOR THE PREPARATION OF BRIDGED LIGAND MONTELL TECHNOLOGY COMPANY BV (NL) 2000-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158356-A1 Process for the preparation of substantially amorphous alpha-olefin polymers and compositions containing them and process for the preparation of bridged ligand MACF1, SDC1, SDC2 MEN1 3563/4885POLB 614/4885KMT2A 3829/4885
US-20020169260-A1 Process for the preparation of ligands for metallocene catalysts SDC1, SDC2, SDC4 MEN1 2357/4885POLB 346/4885KMT2A 3704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.